XOMA Royalty Corporation Depositary Shs Repr 1/1000th 8.375% Cum Conv Perp Red Pfd Rg Shs Series B XOMAO 深 滬
等待開盤 02-06 09:30:00 美东时间
25.30
-0.070
-0.28%
華盛通- 最 高25.335
- 今 開25.335
- 成交量 978股
- 最 低 25.30
- 昨 收 25.3701
- 總市值 4048.00万
- 52周最高 25.4565
- 市盈率 靜 --
- 換手率 0.06%
- 52周最低 21.7497
- 委 比 -98.02%
- 總股本 160.00万
- 歷史最高 25.4565
- 量 比 1.22
- 振 幅 0.14%
- 歷史最低 14.0698
- 每 手 1
- 風險率 0.68%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity
Pyxis Oncology Inc. announced that Thomas Civik has been appointed Interim Chief Executive Officer, succeeding Lara S. Sullivan, M.D., as President, CEO, and CMO. Civik, a board member with extensive biotech experience, will lead the company through its strategic and clinical goals. Lara Sullivan expressed gratitude for her six-year tenure leading the advancement of the lead candidate, MICVO. The company remains focused on advancing MICVO in Phas...
02-03 11:45
XOMA Royalty Appoints New Chief Financial Officer
Xoma ( ($XOMA) ) has shared an update. XOMA Royalty Corporation announced a lea...
01-16 05:48
XOMA Royalty shares are trading lower after the company announced the resignation of CFO Thomas Burns.
XOMA Royalty shares are trading lower after the company announced the resignati...
01-13 01:51
XOMA Royalty announces CFO transition
XOMA Royalty Corporation (XOMA) announced that chief financial officer Thomas Burns will step down. The company has appointed Jeffrey Trigilio as its new CFO as part of the leadership transition. Trig...
01-12 20:44
XOMA Royalty Announces CFO Transition
XOMA Royalty Corporation announced that Chief Financial Officer Thomas Burns is stepping down to pursue other opportunities, after nearly two decades of service. CEO Owen Hughes praised Burns' leadership and dedication, noting the strong financial foundation he built. Burns expressed pride in XOMA Royalty's journey and its established position in the biotech royalty sector. Jeffrey Trigilio has been appointed as the new CFO, bringing extensive ex...
01-12 12:30
Takeda, XOMA ink new royalty agreement; amend existing deal
XOMA Royalty Corporation (XOMA) on Tuesday announced that it reached a new royalty sharing transaction with Takeda (TAK) and amended its existing royalty sharing agreement for the Japanese drugmaker’s...
2025-12-30 21:14
XOMA Royalty Amends Its Collaboration, Originally Established In 2006, With Takeda Through Strategic Royalty Share Transaction
Takeda's royalty and milestone payment obligations to XOMA Royalty related to mezagitamab will be reducedXOMA Royalty will receive payments based on low to mid-single-digit royalties and milestones across a basket of
2025-12-30 20:38
XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab
XOMA Royalty Corporation and Takeda have amended their 2006 collaboration, reducing Takeda’s royalty and milestone payments for mezagitamab while granting XOMA Royalty payments tied to nine development-stage assets in Takeda’s externalized portfolio. This move diversifies XOMA’s portfolio across early- and late-stage programs, balancing risk and opportunity.
2025-12-30 12:30
XOMA Preferred Shares Series A declares $0.5391 dividend
XOMA Preferred Shares Series A (XOMAP) declares $0.5391/share quarterly dividend. Forward yield 8.08% Payable Jan. 15; for shareholders of record Jan. 2; ex-div Jan. 2. See XOMAP Dividend Scorecard, Y...
2025-12-23 04:57
XOMA Corp - 8.375% DP PFD B declares $0.5234 dividend
XOMA Corp - 8.375% DP PFD B (XOMAO) declares $0.5234/share quarterly dividend. Forward yield 8.2% Payable Jan. 15; for shareholders of record Jan. 2; ex-div Jan. 2. See XOMAO Dividend Scorecard, Yield...
2025-12-23 04:56
